Taysha Gene Therapies, Inc.
A pharmaceutical company working in partnership with universities to develop and commercialize adeno-associated virus-based gene therapies focused on monogenic disorders of the central nervous system. The company is developing TSHA-101, a potential treatment for the neurodegenerative disease GM2 gangliosidosis, as well as the neurodevelopmental disorders Rett syndrome and SLC6A1 haploinsufficiency disorder. Delaware-based
Overview
Overview | |
|---|---|
Country | United States |
State | Texas |
Employees | 52 |
Founded | 2019 |
Financials | |
|---|---|
Market Capitalization | 477.27M |
Revenue | 14.16M |
Operating Income | -80.21M |
Operating Margin | -566.61% |
Net Income | -118.00M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 4684 / 5373 |
Sector : Healthcare | 834 / 1144 |
Industry : Biotechnology | 406 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 3032 / 5565 |
Sector : Healthcare | 450 / 1182 |
Industry : Biotechnology | 213 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 4842 / 5436 |
Sector : Healthcare | 930 / 1164 |
Industry : Biotechnology | 494 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 4412 / 5330 |
Sector : Healthcare | 793 / 1174 |
Industry : Biotechnology | 365 / 667 |